Rigel Pharmaceuticals (RIGL) Total Current Liabilities (2010 - 2026)

Rigel Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $89.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 34.31% year-over-year to $89.5 million; the trailing twelve-month figure through Mar 2026 stood at $89.5 million (up 34.31% YoY), and the FY2025 full-year result was $99.2 million, up 56.77% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $89.5 million, down from $99.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $99.2 million in Q4 2025, with the low at $44.0 million in Q2 2023.
• Average Total Current Liabilities over 5 years is $64.9 million, with a median of $59.2 million recorded in 2022.
• Year-over-year, Total Current Liabilities retreated 23.14% in 2023 and soared 73.81% in 2025.
• Tracing RIGL's Total Current Liabilities over 5 years: stood at $65.2 million in 2022, then fell by 18.32% to $53.3 million in 2023, then increased by 18.83% to $63.3 million in 2024, then surged by 56.77% to $99.2 million in 2025, then slipped by 9.82% to $89.5 million in 2026.
• The last three Total Current Liabilities figures came in at $89.5 million (Q1 2026), $99.2 million (Q4 2025), and $94.4 million (Q3 2025), per Business Quant data.

Peer Comparison